COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countriesEng Hooi Tan, Daniel Prieto‐Alhambra, Heba Alghoul et al.|Lara D. Veeken|2021Cited by 53
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Arya Aminorroaya et al.|Journal of the American College of Cardiology|2024Cited by 33
Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort studyErica A. Voss, Rohit Vashisht, Azza Shoaibi et al.|EClinicalMedicine|2023Cited by 27
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Lovedeep Singh Dhingra et al.|BMJ Medicine|2023Cited by 27
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Nicole G. Weiskopf, Talita Duarte‐Salles et al.|Clinical Epidemiology|2022Cited by 26